Current Report Filing (8-k)

---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  02/25/2014

 

ImmunoCellular Therapeutics, Ltd.

(Exact name of registrant as specified in its charter)

 

Commission File Number:  001-35560

 

Delaware		93-1301885
(State or other jurisdiction of		(IRS Employer
incorporation)		Identification No.)

 

23622 Calabasas Road, Suite 300

Calabasas, California 91302

(Address of principal executive offices, including zip code)

 

[phone]

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

 

Item 8.01.    Other Events

 

On February 25, 2014, ImmunoCellular Therapeutics, Ltd. issued a press release entitled, "ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union," a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01.    Financial Statements and Exhibits

 

99.1 Press Release, dated February 25, 2014, entitled, "ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union."

 

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

								ImmunoCellular Therapeutics, Ltd.
Date: February 25, 2014						By:		/s/    Andrew Gengos
								Andrew Gengos
								President and Chief Executive Officer

---

 

EXHIBIT INDEX

 

Exhibit No.		Description
EX-99.1		PRESS RELEASE, DATED FEBRUARY 25, 2014